中国全力开展固体废物综合治理行动 周海兵提出，对工业、建筑、农业等生产环节产生的冶炼渣、尾矿、建筑垃圾、农作物秸秆等固体废 物，在不改变性状的基础上直接利用，提升综合利用能力，特别是加强对其中价值较高成分的高效提取 和整体利用，拓宽综合利用途径。同时，对工业生产和社会生活的各类废弃产品设备进行精细化拆解， 提取塑料、金属、玻璃等再生资源。深挖各类"城市矿产"潜力，鼓励"互联网＋二手"模式发展，大力发 展再制造产业，有序推进海外优质再生资源进口利用。 "伴随工业化、城市化进程，工业废物、建筑垃圾、农林业废物等固体废物快速增加，有效治理固体废 物带来的污染等问题是一个世界性难题。"国家发改委副主任周海兵13日在国务院政策例行吹风会上 说，该部门会同生态环境部、工业和信息化部、住房和城乡建设部、农业农村部等25个部门研究起草了 行动计划。 周海兵说，行动计划突出问题导向，在整合各领域固体废物既有管理手段的基础上，进一步完善全链条 综合治理的政策措施，推动末端治理向全过程防控转变，是中国首个针对固体废物综合治理作出系统性 部署的专项文件，与此前水、土、气污染防治专项文件共同形成了污染防治攻坚战政策体系。 生态环境部副 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ERNEST BOREL HOLDINGS LIMITED 依 波 路 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1856） 持續關連交易 重續現有總產品及服務框架協議 茲提述本公司日期為2022年12月9日的公告，內容有關本公司與本公司控股股東 冠城就（其中包括）現有總產品及服務框架協議進行若干持續關連交易。 由於現有總產品及服務框架協議於2025年12月31日到期，而本公司有意於現有總 產品及服務框架協議到期後在一般日常業務過程中繼續與冠城進行其項下的交易， 於2026年1月13日，本公司與本公司的控股股東冠城訂立重續總產品及服務框架 協議，據此，於重續總產品及服務框架協議期限內，(1)冠城集團可不時提供產品 及服務予本集團，包括(a) 手錶及配件；及(b) 手錶勞務服務；及(2) 本集團可不時 提供產品及服務予冠城集團，包括(a)手錶及配件 ...

Core Viewpoint - The economy is showing resilience and does not appear to be worsening, according to Jamie Dimon, CEO of JPMorgan Chase [1] Economic Outlook - Dimon highlighted that consumer spending remains strong, contributing to economic stability [1] - The job market continues to be robust, with low unemployment rates supporting economic growth [1] Banking Sector Insights - JPMorgan Chase is well-positioned to navigate potential economic challenges due to its diversified business model [1] - The bank's strong capital position allows it to continue lending and supporting clients during uncertain times [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Sundy Service Group Co. Ltd 宋都服务集团有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9608） 須予披露交易 認購結構性存款產品 認購結構性存款產品 為充分利用本集團的閒置資金以獲取更佳回報，於2026年1月13日，本公司附屬 公司宋都物業與杭州銀行訂立結構性存款產品協議，據此，宋都物業同意利用本 集團內部資金向杭州銀行認購人民幣12.0百萬元的結構性存款產品。 上市規則的涵義 由於一項或以上的適用百分比率（定義見上市規則）超過5%，但所有適用百分比 率均低於25%，因此，結構性存款產品協議構成上市規則項下的須予披露交易， 並須遵守上市規則第14章項下的申報及公告規定。 背景 董事會宣佈，為充分利用本集團的閒置資金以獲取更佳回報，於2026年1月13日，本 公司附屬公司宋都物業與杭州銀行訂立結構性存款產品協議，據此，宋都物業同 意利用本 ...

Core Viewpoint - Rivian Automotive's stock has experienced volatility, with a recent decline of 2.74% over the past five trading sessions, following a 4.90% drop previously, and a nearly 15% pullback from its six-month high, although it remains up 41.96% year-over-year [1][2]. Financial Performance - Rivian reported Q3 earnings on November 4, 2025, beating revenue expectations with $1.56 billion against an expected $1.5 billion, but missed on EPS with 65 cents versus the expected 72 cents [2]. - Institutional ownership stands at 56.26%, with Amazon being the largest holder, owning over 158 million shares [2]. - Historical financial data shows Rivian's revenues and net income from 2021 to 2023, with revenues increasing from $55 million in 2021 to $4.434 billion in 2023, while net income remains negative [7]. Production and Capacity - Rivian is working on a new plant in Georgia, expected to open in 2028, and has partnered with Google Maps for a new navigation system for its vehicles [3]. - The company is currently delivering around 13,000 vehicles per quarter and producing 9,000 new G2 vehicles per quarter, aiming for a total production of 57,000 units in 2024 [10]. Cost Management and Profitability - Rivian's next-generation R1 vehicles are designed to reduce component costs by 20% and improve assembly line speed by 30%, with a projected 45% material cost reduction for the R2 line by 2026 [9]. - The company targets positive adjusted EBITDA by 2027, with long-term goals of achieving a 25% gross margin and a 10% free cash flow margin [11]. Market Position and Valuation - Rivian's stock is currently valued at under 3 times sales, compared to Tesla's historical valuation of close to 10 times sales during its early years [12][13]. - The company faces significant competition in the EV market, impacting its valuation and investor sentiment compared to Tesla, which had fewer competitors in its early years [20]. Stock Forecast - Analysts project Rivian's stock price to reach $14.57 by 2026, representing a potential downside of 23.91% from current levels, with a long-term estimate of $44.85 per share by 2030, indicating a potential upside of 128.94% [16][18].

Core Viewpoint - Treace Medical Concepts, Inc. reported preliminary, unaudited revenue results for Q4 and full-year 2025, indicating a mixed performance with a decrease in quarterly revenue but an increase in annual revenue, while emphasizing the company's focus on expanding its market share in bunion procedures and improving profitability [1][9]. Financial Performance - Preliminary revenue for Q4 2025 is estimated to be between $62.1 million and $62.5 million, representing an approximate 9% decrease at the midpoint compared to Q4 2024 [9]. - For the full year 2025, preliminary revenue is projected to be between $212.3 million and $212.7 million, reflecting an approximate 2% increase at the midpoint compared to the previous year, aligning with prior revenue guidance of $211 million to $213 million [9]. Market Position and Strategy - The company experienced mid-single-digit case volume growth in Q4 2025, driven by surgeon adoption of its expanded suite of 3D bunion technologies [3]. - Treace added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, marking a 6% increase year-over-year and representing about 33% of the estimated 10,000 U.S. surgeons performing bunion surgery [9]. Future Outlook - While Treace is not providing full-year 2026 guidance at this time, it anticipates continued positive procedure volume growth, despite facing headwinds from broader economic conditions and a shift in product mix [4]. - The company plans to offer financial guidance for 2026 during its Q4 2025 earnings conference call scheduled for February 26, 2026 [5]. Company Overview - Treace Medical Concepts is focused on advancing surgical management standards for bunions and related midfoot deformities, addressing a significant market with approximately 67 million affected Americans, of which 1.1 million are annual surgical candidates [12]. - The company has developed the Lapiplasty3D Bunion Correction System, which aims to correct bunion deformities in all three planes and secure the unstable joint, thereby addressing the root cause of bunions [12].

Core Insights - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a mixed performance with Q4 revenue growth but an overall decline for the year [1][5]. Financial Performance - Q4 2025 total revenue is expected to be between $20.3 million and $20.4 million, reflecting a 7% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2025 total revenue is projected to be between $77.3 million and $77.4 million, representing a 3% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2025, were approximately $92 million, slightly down from $92.4 million as of September 30, 2025 [4]. Business Developments - The company achieved significant milestones in Dry Eye reimbursement and continued momentum in Surgical Glaucoma, with Dry Eye revenues expected to increase by approximately 130% compared to the prior year [5][7]. - Surgical Glaucoma revenues are anticipated to remain flat at the estimated midpoint compared to the previous year, with expected revenues between $75.6 million and $75.7 million [7]. - The company reported cash used in Q4 totaled approximately $0.4 million, with a total of approximately $28 million used during the year, indicating operational discipline [7]. Future Outlook - The company expressed confidence in its growth outlook and operational discipline, aiming for cash flow breakeven without requiring additional equity capital [5]. - Complete financial results for Q4 and full year 2025 are expected to be announced in March 2026 [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 眾安在綫財產保險股份有限公司 ZHONGAN ONLINE P & C INSURANCE CO., LTD.* （於中華人民共和國註冊成立的股份有限公司，並以「ZA Online Fintech P & C」在香港經營業務） （股份代號：6060） （「第 二 批 票 據」，連 同 首 批 票 據 統 稱「票 據 」） （ 票 據 代 號：40369） 完成贖回票據 （「發行人」） (I) 300,000,000 美元於 2026 年到期的 3.50% 票 據（「 首 批 票 據 」）； 及 (II) 1 00,000,000 美元於 2026 年到期的 3.50% 票 據 （與首批票據合併並形成單一系列） 於完成贖回票據後，概無發行在外的票據。發行人已向香港聯合交易所有限公司申 請撤銷票據的上市地位。有關撤銷上市地位預期將於2026年1月21日營業時間結束 後生效。 香港，2026年1月13日 茲提 ...

亚星化学公告称，公司于2026年1月13日召开董事会，同意终止发行股份及支付现金购买资产并募集配 套资金暨关联交易事项。此前，公司拟购山东天一化学100%股权并募资，交易预计构成重大关联重 组，不构成重组上市。因市场环境变化，各方未就关键事项达成一致。公司股票于2025年11月4日起停 牌。终止交易不会对公司造成重大不利影响，公司承诺1个月内不再筹划重大资产重组，并拟于2月6日 召开投资者说明会。 ...

（文章来源：央视新闻） 乌克兰总统泽连斯基2日在其例行视频讲话中表示，决定调整乌克兰国防部的运作模式，并提议由第一 副总理兼数字转型部部长费奥多罗夫担任国防部长，现任国防部长什梅加尔则将调任其他职位。 当地时间13日，乌克兰最高拉达（议会）在全体会议上投票通过解除国防部长什梅加尔职务的决议，并 通过了关于解除费奥多罗夫数字化转型部部长职务的决议。费奥多罗夫将出任乌克兰国防部长。 ...